Takeda Reports Second Quarter FY2018 Results

Pharmaceutical Investing

Takeda Pharmaceutical (TOKYO:4502) Underlying Revenue +4.2% led by Growth Drivers, with growth in every region. As quoted in the press release: Underlying Revenue was solid at +4.2%, with continued strong momentum from Takeda’s Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets), which grew +9.8%. Key growth products Entyvio (+33.1%) and Ninlaro (+38.0%) were important contributors to …

Takeda Pharmaceutical (TOKYO:4502) Underlying Revenue +4.2% led by Growth Drivers, with growth in every region.

As quoted in the press release:

Underlying Revenue was solid at +4.2%, with continued strong momentum from Takeda’s Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets), which grew +9.8%.
Key growth products Entyvio (+33.1%) and Ninlaro (+38.0%) were important contributors to revenue, as were the products acquired from Ariad in 2017. Every region achieved positive growth versus prior year (U.S. +9.2%, Japan +4.1%, Europe & Canada +4.3%, Emerging Markets +2.4%).

Reported revenue decreased -0.1%. Although our Growth Drivers remained strong, there was a negative impact from foreign exchange rates (-1.0pp) and divestitures (-3.2pp). The divestiture impact included the sale of additional products to the Teva JV in FY2017, and Multilab and Techpool in FY2018.

Click here to read the full press release.

The Conversation (0)
×